Actively Recruiting
Effect of Pentoxyfilline on Endometrial Thickness and Frozen Embryo Transfer Outcomes
Led by Beni-Suef University · Updated on 2026-03-30
100
Participants Needed
1
Research Sites
4 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are evaluating the effect of different vasodilators, specifically pentoxifylline, in women with unexplained infertility who are undergoing in vitro fertilization (IVF) using frozen embryo transfer. This prospective randomized clinical study includes women aged 18 to 43 years with good quality day five frozen embryos. The study was approved by the Ethical Committee of Beni Suef University Hospitals in Egypt, and informed consent was obtained from participants. Participants are randomly assigned into two groups. The control group receives estradiol valerate 2 mg tablets starting at one pill three times daily, which may be increased based on endometrial thickness measured by vaginal ultrasound on day 9. The experimental group receives pentoxifylline 400 mg once daily in addition to the estradiol valerate treatment, starting from the first day of the cycle until the day progesterone treatment begins. During the study, all participants undergo thorough history taking, physical examination, and laboratory tests including hormone levels (AMH, FSH, LH, estradiol, prolactin, TSH), as well as ultrasonography to assess endometrial thickness. The primary outcome measured is pregnancy status at one month. The total participation duration varies according to the treatment cycle and monitoring schedule, with ongoing assessments to evaluate treatment effects on embryo transfer outcomes.
CONDITIONS
Brief Title
Effect of Pentoxyfilline on Endometrial Thickness and Frozen Embryo Transfer Outcomes
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Women with good quality day five frozen embryos
- Aged between 18 and 43 years
- Female gender
You will not qualify if you...
- History of endocrine diseases
- Previous surgery that could affect the uterine lining
- Cardiovascular diseases
- Kidney diseases
- Liver diseases
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - From the first day of the cycle until the day of starting progesterone
Participants receive estradiol valerate pills with dosage adjusted based on ultrasound assessment of endometrial thickness. Some participants also receive pentoxifylline daily from the first day of the cycle until the start of progesterone.
At least 1 ultrasound visit around day 9 of the cycle
Duration - 1 month
Participants are followed to assess pregnancy outcomes one month after treatment.
1 follow-up visit (in-person)
Trial Site Locations
Total: 1 location
1
Beni-suef university Hospital
Banī Suwayf, Beni Suweif Governorate, Egypt, 62521
Actively Recruiting
Research Team
S
Sara A Salem, MD
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here